NCT03636204View on ClinicalTrials.gov

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
HealthyFrontotemporal Dementia
Interventions
BIOLOGICAL

AL001

Active dose of AL001

OTHER

Placebo

Saline solution administered as a single infusion as palcebo.

Trial Locations (8)

19104

University of Pennsylvania, Philadelphia

32806

Study site, Orlando

35294

University of Alabama, Birmingham

55905

Mayo Clinic, Rochester

94158

UCSF, San Francisco

Unknown

Lawson Health Research Institute, St. Joseph's, London

Sunnybrook Health Sciences Centre, Toronto

WC1N 3BG

University College London, London

Sponsors

Lead Sponsor

Alector Inc.
All Listed Sponsors
lead

Alector Inc.

INDUSTRY